<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906750</url>
  </required_header>
  <id_info>
    <org_study_id>FMRESP</org_study_id>
    <nct_id>NCT00906750</nct_id>
  </id_info>
  <brief_title>A Study of a Live Intranasal Influenza Vaccine in Children With Cancer</brief_title>
  <acronym>FMRESP</acronym>
  <official_title>A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible research subjects will be randomized to receive either FluMist or inactivated&#xD;
      influenza vaccine then stratified by age and necessity to receive either one or two&#xD;
      immunizations. Subjects requiring one immunization will be immunized at Day 0. Subjects&#xD;
      requiring two immunizations will be immunized at Day 0 and Day 28. Subjects will be observed&#xD;
      for 30 minutes following vaccination and given a diary card to record symptoms after each&#xD;
      vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are to:&#xD;
&#xD;
        1. Describe the safety of FluMist and inactivated influenza vaccine.&#xD;
&#xD;
        2. Describe the incidence and duration of viral replication following immunization with&#xD;
           FluMist.&#xD;
&#xD;
        3. To examine the association between immunization response (seroconversion or&#xD;
           seroprotection) and baseline clinical factors (age, type of malignancy, absolute&#xD;
           neutrophil count, absolute lymphocyte count, serum IgA, IgG and IgM levels).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to describe the immune response of FluMist compared with inactivated influenza vaccine in mild to moderately immunocompromised children with cancer</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunization response</measure>
    <time_frame>10/31/2010</time_frame>
    <description>To examine the association between immunization response (seroconversion or seroprotection) and baseline clinical factors (age, type of malignancy, absolute neutrophil count, absolute lymphocyte count, serum IgA, IgG and IgM levels).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flumist safety</measure>
    <time_frame>2 years</time_frame>
    <description>Describe the safety of FluMist and inactivated influenza vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Replication</measure>
    <time_frame>1 year</time_frame>
    <description>Describe the incidence and duration of viral replication following immunization with FluMist.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
    <description>FluMist is a live attenuated intranasal influenza vaccine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated influenza vaccine</intervention_name>
    <description>Inactivated influenza vaccine</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 2 through 21 (not yet reached their 22nd birthday) at the time of entry into the&#xD;
             study&#xD;
&#xD;
          -  Participant or participants parent/legal guardian available by telephone during the&#xD;
             course of the study;&#xD;
&#xD;
          -  Written informed consent (and assent, if applicable) obtained&#xD;
&#xD;
          -  Currently receiving chemotherapy and /or radiotherapy for the treatment of cancer or&#xD;
             have received chemotherapy in the past 12 weeks;&#xD;
&#xD;
          -  If the participant's underlying cancer is a solid tumor, current status must be stable&#xD;
             disease, partial response, or complete response to therapy; if the participant's&#xD;
             underlying disease is a hematological malignancy, current status must be in remission,&#xD;
             and if receiving chemotherapy, must be in the &quot;continuation&quot; or &quot;maintenance&quot; phase of&#xD;
             therapy or equivalent;&#xD;
&#xD;
          -  Estimated life expectancy of &gt; 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any component of FluMist or TIV, including egg or egg&#xD;
             products, gelatin, or monosodium glutamate;&#xD;
&#xD;
          -  History of hypersensitivity to gentamicin;&#xD;
&#xD;
          -  Close contact with a severely immunocompromised patient (e.g., a hematopoietic stem&#xD;
             cell transplant patient, during those periods in which the immunocompromised patient&#xD;
             requires care in a protective environment&#xD;
&#xD;
          -  History of Guillain-BarreÂ´ syndrome;&#xD;
&#xD;
          -  History of asthma;&#xD;
&#xD;
          -  Female who is breastfeeding or lactating;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvana Carr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FLuMIST</keyword>
  <keyword>Inactivated influenza vaccine</keyword>
  <keyword>Study of FluMist versus inactivated influenza vaccine in children with cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

